Oncoinvent ASA
0RU5.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.49B
Close$
Share Statistics
| Market cap | $9.49 Billion |
|---|---|
| Enterprise Value | $9.39 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-125.13 |
| Beta | 0.39 |
| Outstanding Shares | 246,872,323 |
Return
| Return on Equity | -345.68% |
|---|---|
| Return on Assets | -217.36% |
| Return on Invested Capital | -327.23% |
Valuation & Multiples
| P/E Ratio | -0.84 |
|---|---|
| PEG | -3.26 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 376.86 |
| Enterprise Value to EBIT | -35.58 |
| Enterprise Value to Net Income | -34 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 27, 2026
EPS Estimate
$-591.85
Average shareholder expectationRevenue Estimate
$9.37 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Oncoinvent ASA
44 employees
CEO: Oystein Soug Oncoinvent ASA is a biopharmaceutical firm dedicated to creating novel therapies for cancer. The company concentrates its efforts on building a diverse range of AXL kinase inhibitors. Its flagship product, bemcentinib, stands out as a hi...